Lansodor

Lansoprazole, the active ingredient in Lansodor, is a proton pump inhibitor presented as an oral tablet for systemic use. It reduces gastric acid production and is prescribed for conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and Helicobacter pylori eradication regimens, typically in adult patients.

GNH USA supplies Lansodor as a licensed, GDP‑compliant international pharmaceutical product, providing reliable supply to hospitals, pharmacies and clinics worldwide while adhering to EU quality standards and offering global logistics support.

Lansodor, a proton pump inhibitor, is used to manage acid‑related gastrointestinal disorders.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and promotes symptom relief. - Erosive esophagitis: facilitates healing of inflamed esophageal tissue. - Peptic ulcer disease: promotes ulcer healing by lowering gastric acidity. - Helicobacter pylori eradication: used as part of combination therapy to increase eradication rates.

Lansodor is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: feeling of stomach upset, usually mild. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe diarrhea with abdominal pain. - Stevens‑Johnson syndrome: skin blistering and mucosal involvement. - Elevated liver enzymes: signs of hepatic stress. - Hypomagnesemia: low magnesium levels with prolonged use. - Acute pancreatitis: sudden abdominal pain radiating to the back.

Before initiating Lansodor, consider the following safety measures.

- Assess renal function: adjust therapy in patients with severe impairment. - Monitor for drug interactions: especially with clopidogrel, atazanavir or methotrexate. - Use with caution in the elderly: higher risk of fractures and electrolyte disturbances. - Avoid in known hypersensitivity: discontinue if rash or angioedema develops. - Store at room temperature: keep in the original container, protect from moisture and light.

Lansodor may interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, compromising antiviral efficacy. - Methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Diazepam: elevated plasma levels may enhance sedation. - Digoxin: may raise serum concentration, necessitating dose adjustment.